https://www.businesswire.com/news/home/20180530006605/en/

OAKLAND, Calif.--(BUSINESS WIRE)--May 31, 2018--Riffyn, a provider of cloud-based R&D software, announces that Per Falholt and Devendra Deshmukh have joined Riffyn’s Advisory Board. Mr. Falholt previously served as the head of Novozymes R&D. Mr. Deshmukh most recently served as the Executive Director of R&D IT at Merck Sharp & Dohme.

“We are thrilled to have Per and Devendra join our Advisory Board,” noted Dr. Timothy Gardner, Riffyn’s Founder/CEO. “As the head of Novozymes R&D, Per was an enthusiastic force for scientific and digital innovation — a perspective that translates perfectly to Riffyn’s culture and business. Likewise, Devendra brings deep experiences deploying transformative technology solutions in the life sciences industry from his career at Merck, PerkinElmer, CambridgeSoft, and elsewhere.”